<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588809</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00250</org_study_id>
    <secondary_id>15455B</secondary_id>
    <secondary_id>N01CM62209</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <nct_id>NCT00588809</nct_id>
  </id_info>
  <brief_title>Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 2 Study of AZD6244 in Relapsed or Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II clinical trial is studying how well selumetinib works in treating patients with
      recurrent or refractory acute myeloid leukemia. Selumetinib may stop the growth of cancer by
      blocking some of the enzymes needed for cell growth
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the response rate (includes complete response-CR, complete response with
      incomplete count recovery CRi, partial response-PR, and minor response-MR) to AZD6244
      (selumetinib).

      SECONDARY OBJECTIVES:

      I. To determine the effects of AZD6244 in AML samples on p-ERK and evaluate the potential
      utility of p-ERK inhibition as a surrogate marker of biologic activity.

      II. To correlate the effects of AZD6244 with the presence (or absence) of mutated RAS or
      FLT-3 at baseline.

      III. To assess the safety profile of AZD6244 in patients with AML.

      OUTLINE:

      Patients receive selumetinib orally (PO) twice daily (BID) on days 1 -28. Treatment repeats
      every 4 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate for Subjects Without FLT3 ITD Mutation</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Responses were defined using standard criteria developed by an International Working Group.
[Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.]
In this primary outcome, we report the proportion of subjects without FLT3 ITD mutation that experienced a complete response (CR), partial response (PR), minor response (MR), or unconfirmed minor response (uMR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Baseline p-ERK Activation</measure>
    <time_frame>baseline (0 weeks)</time_frame>
    <description>Proportion of subjects with baseline p-ERK activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With NRAS Mutation</measure>
    <time_frame>baseline (0 weeks)</time_frame>
    <description>Proportion of Subjects With NRAS Mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With KRAS Mutation</measure>
    <time_frame>baseline (0 weeks)</time_frame>
    <description>Proportion of subjects with KRAS mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With FLT3 ITD Mutation</measure>
    <time_frame>baseline (0 weeks)</time_frame>
    <description>Proportion of subjects with FLT3 ITD mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With KIT Mutation</measure>
    <time_frame>baseline (0 weeks)</time_frame>
    <description>Proportion of subjects with KIT mutation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Promyelocytic Leukemia (M3)</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (selumetinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (selumetinib)</arm_group_label>
    <other_name>ARRY-142886</other_name>
    <other_name>AZD6244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of 1 of the following:

               -  Relapsed or refractory acute myeloid leukemia (AML)

               -  Secondary AML including AML arising from antecedent hematologic diseases (e.g.,
                  myelodysplastic syndrome, myeloproliferative disorders, or therapy-related AML)

          -  Elderly patients ≥ 60 years of age, previously untreated, and who are not candidates
             for or have refused standard chemotherapy are eligible for this trial

          -  Patients with relapsed acute promyelocytic leukemia (APL) who are FLT3+ and have
             failed both tretinoin and arsenic therapy are eligible for this trial

          -  No known active CNS disease

          -  ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%

          -  Total bilirubin ≤ 2 mg/dL (unless due to disease, hemolysis, or Gilbert disease)

               -  In patients with associated hemolysis or Gilbert disease, a bilirubin of &gt; 2
                  mg/dL is allowed as a result of predominantly unconjugated hyperbilirubinemia

          -  AST/ALT &lt; 3 times upper limit of normal

          -  Creatinine &lt; 2 mg/dL

          -  Baseline pulse oximetry &gt; 92%

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception prior to, during, and for 4 weeks
             (16 week for males) after completion of study treatment

          -  Recovered from prior therapy

          -  At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or
             radiotherapy

               -  Hydroxyurea may be administered for the first 7 days of therapy in patients with
                  rapidly rising white count (WBC &gt; 20 K/μL)

          -  At least 4 weeks since prior investigational agents

          -  No prior MEK inhibitors

          -  No concurrent medication that can prolong the QT interval

          -  No other concurrent investigational agents

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

        Exclusion Criteria:

          -  History of allergic reactions attributed to compounds of similar chemical or
             biological composition to AZD6244 or its excipient Captisol®

          -  QTc interval &gt; 450 msecs or other factors that increase the risk of QT prolongation or
             arrhythmic events (e.g., heart failure, hypokalemia, or family history of long QT
             interval syndrome), including New York Heart Association class III or IV heart failure

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory
             bowel disease), or significant bowel resection that would preclude adequate absorption

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or psychiatric illness or social situations that would limit compliance with
             study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olatoyosi Odenike</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. Erratum in: J Clin Oncol. 2004 Feb 1;22(3):576. LoCocco, Francesco [corrected to Lo-Coco, Francesco].</citation>
    <PMID>14673054</PMID>
  </reference>
  <results_reference>
    <citation>Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15;20(2):490-8. doi: 10.1158/1078-0432.CCR-13-1311. Epub 2013 Oct 31.</citation>
    <PMID>24178622</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <results_first_submitted>July 6, 2015</results_first_submitted>
  <results_first_submitted_qc>July 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2015</results_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A Simon, optimal two-stage design was employed for subjects without FLT3 ITD mutations. The study also included a second cohort of subjects with FLT3 ITD mutations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Selumetinib</title>
          <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Selumetinib</title>
          <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="26" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate for Subjects Without FLT3 ITD Mutation</title>
        <description>Responses were defined using standard criteria developed by an International Working Group.
[Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–9.]
In this primary outcome, we report the proportion of subjects without FLT3 ITD mutation that experienced a complete response (CR), partial response (PR), minor response (MR), or unconfirmed minor response (uMR).</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Analysis only includes subjects without FLT3 ITD mutation.</population>
        <group_list>
          <group group_id="O1">
            <title>Selumetinib</title>
            <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate for Subjects Without FLT3 ITD Mutation</title>
          <description>Responses were defined using standard criteria developed by an International Working Group.
[Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–9.]
In this primary outcome, we report the proportion of subjects without FLT3 ITD mutation that experienced a complete response (CR), partial response (PR), minor response (MR), or unconfirmed minor response (uMR).</description>
          <population>Analysis only includes subjects without FLT3 ITD mutation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Baseline p-ERK Activation</title>
        <description>Proportion of subjects with baseline p-ERK activation</description>
        <time_frame>baseline (0 weeks)</time_frame>
        <population>The analysis includes the 20 patients with samples available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Selumetinib</title>
            <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Baseline p-ERK Activation</title>
          <description>Proportion of subjects with baseline p-ERK activation</description>
          <population>The analysis includes the 20 patients with samples available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With NRAS Mutation</title>
        <description>Proportion of Subjects With NRAS Mutation</description>
        <time_frame>baseline (0 weeks)</time_frame>
        <population>The analysis includes the 41 patients with samples available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Selumetinib</title>
            <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With NRAS Mutation</title>
          <description>Proportion of Subjects With NRAS Mutation</description>
          <population>The analysis includes the 41 patients with samples available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With KRAS Mutation</title>
        <description>Proportion of subjects with KRAS mutation</description>
        <time_frame>baseline (0 weeks)</time_frame>
        <population>The analysis includes the 41 patients with samples available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Selumetinib</title>
            <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With KRAS Mutation</title>
          <description>Proportion of subjects with KRAS mutation</description>
          <population>The analysis includes the 41 patients with samples available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With FLT3 ITD Mutation</title>
        <description>Proportion of subjects with FLT3 ITD mutation</description>
        <time_frame>baseline (0 weeks)</time_frame>
        <population>FLT3 ITD mutation status was not available for one patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Selumetinib</title>
            <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With FLT3 ITD Mutation</title>
          <description>Proportion of subjects with FLT3 ITD mutation</description>
          <population>FLT3 ITD mutation status was not available for one patient.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With KIT Mutation</title>
        <description>Proportion of subjects with KIT mutation</description>
        <time_frame>baseline (0 weeks)</time_frame>
        <population>The analysis includes the 41 patients with samples available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Selumetinib</title>
            <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With KIT Mutation</title>
          <description>Proportion of subjects with KIT mutation</description>
          <population>The analysis includes the 41 patients with samples available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Selumetinib</title>
          <description>Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
selumetinib: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>A disorder characterized by an reduction in the amount of hemoglobin in 100 ml of blood.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>A disorder characterized by an ANC &lt;1000/mm3 and a single temperature of &gt;38.3 degrees C (101 degrees F) or a sustained temperature of &gt;=38 degrees C (100.4 degrees F) for more than one hour</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <description>A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>A disorder characterized by frequent and watery bowel movements.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>A disorder characterized by reduced salivary flow in the oral cavity.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>A disorder characterized by inflammation of the oral mucosal.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>A disorder characterized by a queasy sensation and/or the urge to vomit.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <description>A cessation of life that cannot be attributed to a CTCAE term associated with Grade 5.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>A disorder characterized by elevation of the body's temperature above the upper limit of normal.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Blood</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Salivary gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L): Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils: Blood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>A disorder characterized by an infectious process involving the lungs.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>A disorder characterized by inflammation of the throat.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause a rapidly progressing systemic reaction that may lead to shock.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>A disorder characterized by a loss of appetite.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <description>A disorder characterized by a reduction in the strength of the lower limb muscles.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <description>A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <description>A disorder characterized by bleeding from the cranium.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <description>A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <description>A disorder characterized by a change in the color of the urine.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <description>A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>A disorder characterized by an uncomfortable sensation of difficulty breathing.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>A disorder characterized by bleeding from the nose.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>A disorder characterized by a decrease in the level of oxygen in the body.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>A disorder characterized by an reduction in the amount of hemoglobin in 100 ml of blood.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>A disorder characterized by an ANC &lt;1000/mm3 and a single temperature of &gt;38.3 degrees C (101 degrees F) or a sustained temperature of &gt;=38 degrees C (100.4 degrees F) for more than one hour</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>A disorder characterized by a dysrhythmia without discernible P waves and an irregular ventricular response due to multiple reentry circuits. The rhythm disturbance originates above the ventricles.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Paroxysmal atrial tachycardia</sub_title>
                <description>A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <description>A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>A disorder characterized by swelling of the abdomen.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>A disorder characterized by a sensation of marked discomfort in the abdominal region.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>A disorder characterized by irregular and infrequent or difficult evacuation of the bowels.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>A disorder characterized by frequent and watery bowel movements.</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>A disorder characterized by reduced salivary flow in the oral cavity.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <description>A disorder characterized by the presence of dilated veins in the rectum and surrounding area.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>A disorder characterized by inflammation of the oral mucosal.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>A disorder characterized by a queasy sensation and/or the urge to vomit.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <description>A disorder characterized by bleeding from the mouth.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <description>A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <description>A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>A disorder characterized by elevation of the body's temperature above the upper limit of normal.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>A disorder characterized by discomfort in the chest unrelated to a heart disorder.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>A disorder characterized by the sensation of marked discomfort, distress or agony.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>A disorder characterized by an adverse local or general response from exposure to an allergen.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <description>A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>A disorder characterized by a loss of appetite.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>A disorder characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>A disorder characterized by a sensation of marked discomfort in a joint.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>A disorder characterized by marked discomfort sensation in the back region.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <description>A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <description>A disorder characterized by a reduction in the strength of the lower limb muscles.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <description>A disorder characterized by a lack of clear and orderly thought and behavior.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>A disorder characterized by melancholic feelings of grief or unhappiness.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound.</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>A disorder characterized by an uncomfortable sensation of difficulty breathing.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>A disorder characterized by bleeding from the nose.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>A disorder characterized by a decrease in the level of oxygen in the body.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <description>A disorder characterized by marked discomfort sensation in the pharyngolaryngeal region.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <description>A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <description>A disorder characterized by excessive perspiration.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <description>A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <description>A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>A disorder characterized by a pathological increase in blood pressure; a repeatedly elevation in the blood pressure exceeding 140 over 90 mm Hg.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Olatoyosi Odenike, MD</name_or_title>
      <organization>The University of Chicago Medicine</organization>
      <phone>(773) 702-6149</phone>
      <email>todenike@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

